Drug Profile
Pazufloxacin - Lee''s Pharmaceutical
Alternative Names: Pazufloxacin mesilate - Lee's PharmaceuticalLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Lee's Pharmaceutical
- Class Anti-infectives; Antibacterials; Fluoroquinolones; Oxazines; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Otitis media
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Otitis-media in China (Otic, Drops)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Otitis-media in China (Otic, Drops)
- 29 Jul 2018 Pazufloxacin is still in phase I trials for Otitis media in China (NCT03675841)